-

Forge Biologics to Present at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a hybrid gene therapy contract manufacturing and clinical stage therapeutic development company, announced today that it will be presenting at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit, being held virtually April 26-27, 2021.

Forge Chief Executive Officer, President, and Co-Founder Timothy J. Miller, Ph.D., will be joined by David Dismuke, Ph.D., the company’s Chief Technical Officer, in a fireside chat format to be moderated by Chardan analyst Gbola Amusa on April 26 at 2:30 p.m. The Forge team will also participate in one-on-one meetings during the conference.

Chardan's 5th Annual Genetic Medicines Manufacturing Summit features leading companies, academics and thought leaders focused on advancing genetic medicines.

“We are honored and grateful to be participating at this exclusive event hosted by Chardan during such an exciting time for Forge Biologics, as we continue to grow our team and our facility with our vision focused sharply on significantly advancing gene therapy manufacturing capabilities,” said Dr. Miller.

The virtual event is limited to current or prospective relationships of Chardan, but Forge’s company presentation video will be available to view after the conference on its website at https://www.forgebiologics.com/news/.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 ft2 facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

For more information, please visit www.forgebiologics.com.

Contacts

Media Inquiries:
Dan Salvo
Director of Communications and Community Development
Forge Biologics Inc.
media@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President and Head of Business Development
Forge Biologics Inc.
BD@forgebiologics.com

Investor Relations
Christina Perry
Vice President, Finance and Operations
Forge Biologics Inc.
Investors@forgebiologics.com

Patient, Pediatrician, Genetic Counselors & Family Inquiries
Dr. Maria Escolar
Chief Medical Officer
Forge Biologics Inc.
medicalaffairs@forgebiologics.com

Forge Biologics Inc.


Release Summary
Forge Biologics to Present at Chardan’s Genetic Medicines Manufacturing Summit.
Release Versions

Contacts

Media Inquiries:
Dan Salvo
Director of Communications and Community Development
Forge Biologics Inc.
media@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President and Head of Business Development
Forge Biologics Inc.
BD@forgebiologics.com

Investor Relations
Christina Perry
Vice President, Finance and Operations
Forge Biologics Inc.
Investors@forgebiologics.com

Patient, Pediatrician, Genetic Counselors & Family Inquiries
Dr. Maria Escolar
Chief Medical Officer
Forge Biologics Inc.
medicalaffairs@forgebiologics.com

Social Media Profiles
More News From Forge Biologics Inc.

Avista Therapeutics and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership

PITTSBURGH & COLUMBUS, Ohio--(BUSINESS WIRE)--Avista Therapeutics (“Avista”), a pre-clinical-stage biotechnology company developing novel AAV capsids with high efficacy and unique tropisms into innovative gene therapies for rare ophthalmic conditions, and Forge Biologics, (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to advance the development and manufacturing of AVST-101, Avista’s lead gene...

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV development and manufacturing agreement to help advance Fractyl Health’s Rejuva* pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes (T2D). "We developed our FUEL™ platform to provide developers like Fractyl with a more efficient and scalable manufacturing solution to help...

Forge Biologics Announces Eight Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver eight presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025 in New Orleans, Louisiana. The presentations include two technical session presentations, an oral presentation, and five scientific posters focused on Forge’s FUEL™ pl...
Back to Newsroom